Supplementary Material - Drug survival of adalimumab is superior to infliximab in pediatric patients with hidradenitis suppurativa

Supplementary figures depicting biologic survival in biologic naïve versus biologic non-naïve patients (1) and patients with pelvic HS disease versus no pelvic HS disease (2).

Supplementary tables depicting demographic Information for each biologic cohort (1), additional Cox proportional hazards regression analysis for our adalimumab cohort (2), and unadjusted Cox proportional hazards regression analysis for our infliximab cohort (3).